Research Article
Is the 5-iodo-2-aminoindan (5-IAI) the New MDMA?
Coppola M1* and Mondola R21Department of Addiction, ASL CN2, Viale Coppino 46, 12051, Alba (CN), Italy
2Department of Mental Health, ASL CN1, Via Torino 70/B, 12037, Saluzzo (CN), Italy
- *Corresponding Author:
- Coppola M
Department of Addiction
ASL CN2, Viale Coppino 46
12051, Alba (CN), Italy
Tel: +390173316210
Fax: +390173420344
E-mail: coppolamail@alice.it
Received August 28, 2012; Accepted September 22, 2012; Published September 30, 2012
Citation: Coppola M, Mondola R (2012) Is the 5-iodo-2-aminoindan (5-IAI) the New MDMA? J Addict Res Ther 3:134. doi:10.4172/2155-6105.1000134
Copyright: © 2012 Coppola M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Between 1997 and 2011, more than 200 new substances have been officially notified in European Union via the Early Warning System with the largest number of compounds ever reported in a single year in 2011 (49 substances). In 2010, an internet snapshot anticipated the presence of 5-iodo 2-aminoindan (5-IAI) within the recreational drug market. In 2011, this compound, a psychoactive analog of p-iodoamphetamine, was identified in United Kingdom. The aim of this paper is to summarize the clinical, pharmacological and toxicological information currently available about this new potential recreational drug.